Clinical trials: Circulating Tumor DNA (ctDNA)
Esophageal Cancer
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with…
- Trial name
- MRD2START (NCT06914011)
- Testing
- Tislelizumab
- Volunteers
- 172 people
- Sponsor
- Asan Medical Center
Breast Cancer, Breast Neoplasms
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
The primary aim of the study is to identify genomic markers (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), transcriptomic markers) as biomarkers of response to neoadjuvant chemotherapy (NAC) among patients with…
- Conditions
- Breast Cancer, Breast Neoplasms, Cancer, Breast
- Trial name
- NCT03709134
- Testing
- Genomic Markers (CTC/ctDNA)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Gastric Cancer
Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
This study aims to evaluate the clinical value of circulating tumor DNA (ctDNA) as a minimally invasive biomarker for monitoring treatment response and guiding systemic therapy in patients with gastric or gastroesophageal…
- Trial name
- NCT07517107
- Testing
- Circulating Tumor DNA (ctDNA) Analysis, Standard Systemic Therapy for Gastric Cancer
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fudan University
Colorectal Cancer, Peritoneal Metastases
ctDNA as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer
This is a prospective, open-label, randomized controlled clinical trial, by monitoring the serum ctDNA mutational profile using NGS, aiming to elucidate the correlation between the postoperative ctDNA status and the assisted…
- Trial name
- NCT04752930
- Testing
- ctDNA monitoring, Imageology
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer
Circulating Tumor DNA Methylation Guiding Postoperative Adjuvant Chemotherapy in Stage III Colorectal Cancer
The goal of this randomized controlled trial is to investigate whether ctDNA methylation is a more precise indicator to guide postoperative adjuvant chemotherapy in stage Ill colorectal cancer.
- Trial name
- cmPAT (NCT06167967)
- Testing
- ctDNA methylation, standard treatment
- Where
- China
- Volunteers
- 990 people
- Sponsor
- Sir Run Run Shaw Hospital
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
The purpose of this prospective biospecimen collection study is to evaluate the feasibility of measuring circulating tumor DNA (ctDNA) in subjects with muscle-invasive bladder cancer (MIBC) treated with trimodality therapy…
- Trial name
- NCT05630131
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Gastric Cancer (GC), Pancreatic Cancer
Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA
The peritoneum is a relatively frequent metastatic site in digestive tumors (colon, stomach, pancreas) and is characterized by a poorer prognosis compared with other metastatic sites such as the lung or liver.
- Conditions
- Gastric Cancer (GC), Pancreatic Cancer, Colorectal Cancer
- Trial name
- PREDIPER (NCT07574957)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non Small Cell Lung Cancer
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery.
- Trial name
- DNA-PREDICT (NCT06902272)
- Testing
- Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Circulating Tumor DNA, Recurrence
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
Patients in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) with non-metastatic colon cancer that gave consent for additional blood withdrawals are enrolled in the observational PLCRC-MEDOCC substudy.
- Conditions
- Circulating Tumor DNA, Recurrence, Colon Cancer Stage II
- Trial name
- CrEATE (NCT06434896)
- Testing
- ctDNA analysis after surgery
- Where
- 29 sites in Netherlands
- Volunteers
- 1,320 people
- Sponsor
- UMC Utrecht
Lymphomas
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques
Lymphomas are the most common haemopathic malignancy. The 3 most common types are diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL) and follicular lymphoma (FL).
- Trial name
- BIOLYMPH2020 (NCT04417803)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Vulva Cancer, Vulva Neoplasm
Danish Vulva Cancer Recurrence Study
The overall aim is to investigate different aspects of recurrence detection in women with vulva cancer (VC) to identify optimal treatment- and surveillance programs.
- Conditions
- Vulva Cancer, Vulva Neoplasm, Vulvar Cancer, Vulva Disease
- Trial name
- DaVulvaRec (NCT06495554)
- Testing
- Measurement of circulating tumor-DNA, Collection of patient-reported outcomes, Algorithmically determined telephone interview with a nurse
- Where
- 2 sites in Denmark
- Volunteers
- 1,295 people
- Sponsor
- University of Aarhus
Resectable Pancreatic Cancer
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if…
- Trial name
- CIRCPAC (NCT05788744)
- Testing
- ctDNA
- Where
- 5 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- Copenhagen University Hospital at Herlev
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04489719
- Testing
- Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
Carcinoma, Non-small-cell Lung Cancer
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
Analyse immune repertoire and genetic mutations of benign and malignant pulmonary nodule，and evaluate peripheral blood detection for identifying nature of pulmonary nodule.
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasm
- Trial name
- NCT03320044
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Breast Cancer
CIrCuLAting Dna ESr1 Gene Mutations Analysis
The estrogen-dependent nature of breast cancer was first reported in 1896 with the publication of George Beatson's observations on the regression of breast cancer following oophorectomy.
- Trial name
- CICLADES (NCT03318263)
- Testing
- next-generation sequencing (NGS)
- Where
- 10 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut de Cancérologie de Lorraine
Metastatic Breast Cancer
Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer
The purpose of this study is to evaluate whether increased mutant ESR1 allele fraction in plasma ctDNA 3-6 weeks after initiating salvage endocrine therapy is predictive of progression free survival in patients with ER+…
- Trial name
- NCT03161834
- Testing
- Observational
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Diffuse Large B Cell Lymphoma
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Patients suffering from diffuse large B-cell lymphoma (DLBCL) who relapse within 12 months of chemotherapy usually undergo salvage therapies, followed by autologous transplant with a low success rate.
- Trial name
- NCT03311958
- Testing
- Nivolumab, IV, 240 mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fox Chase Cancer Center
Biliary Tract Cancer
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
This prospective, multicenter, observational study aims to evaluate the role of circulating tumor DNA (ctDNA) in advanced or metastatic biliary tract cancer (BTC) patients in Korea.
- Trial name
- NCT07151118
- Testing
- Blood Sampling for ctDNA Analysis
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHA University
Colorectal Cancer
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient.
- Trial name
- NCT06098560
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Lung Neoplasms
Circulating Tumor DNA in Surgical Lung Cancer Patients
Conduct a prospective study to detect the change of ctDNA of surgical lung cancer patients.
- Trial name
- NCT03081741
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shenzhen Gene Health Bio Tech Co., Ltd.